Barbara Pro
@bpromd
Lymphoma Doc @columbiacancer @nyphospital Tweets are my own
Some personal news….after 6 great years @LurieCancer I joined @columbiacancer as director of the lymphoma program. I am thrilled to be working with an exceptional group of clinical reasearchers and scientists to advance the understanding and treatment of lymphoma. #lymsm
Up next 💥Should we treat smoldering myeloma now? Yes or not ? 💥with @DrOlaLandgren and @SLentzsch chaired by @szusmani
Great discussion 👏on #MDS at Medical Crossfire 💥with @Dr_AmerZeidan @yasminabaza1 & Dr @Ramikomrokji #MXH25
Results from 4 pivotal phase 3 trials (MIDAS, PERSEUS, IsKIA, ADVANCE) representing current thinking on the role of ASCT in NDMM, masterfully summarized and contextualized by @SLentzsch! #ASCO25 #MYELOMA #MRD @columbiacancer
Suzanne Lentzsch receives the CoMy award for women’s achievement in MM very deserved and supported by her family and work colleagues
🗽 Big debates. Bold insights. Live in New York. Join us for the 9th Annual #MXH25 — a one-day, fast-paced event where experts tackle today’s most pressing challenges in hematologic cancer. HCPs save 75% with code MXH75: bit.ly/4jIw2wE @bpromd @szusmani @Dr_AmerZeidan
Start spreadin’ the news… we’re headed to New York for the 9th Annual Live Medical Crossfire®: Hematologic Malignancies! Join @bpromd @szusmani @Dr_AmerZeidan for expert-led debates and real-time insights! 🗽Get 75% off HCP registration with code MXH75 bit.ly/4jIw2wE
Combination JAK inhibition and Immune checkpoint blockade being presented by @SedaToluMD 👏 @columbiacancer #ASH2024 #ASH24
Unlocking the potential of epigenetic therapies! @SedaToluMD and colleagues explore the promise of combining epigenetic agents with other treatments to enhance outcomes in @NatRevClinOncol oncodaily.com/url/197882 @TheDoctorIsVin @jenamengual @bpromd @susanebates #Cancer…
🩸🧬Happy to share this @ForesightDx release ahead of #ASH24 on our MRD-guided study for newly diagnosed DLBCL is now open at @columbiacancer! The overall goal is to de-escalate cytotoxic chemotherapy for early molecular responders #lymsm #mrd clinicaltrials.gov/study/NCT06693…
We are pleased to share that our Foresight CLARITY #MRD test will be used in @ColumbiaMed's SHORTEN-ctDNA trial, which aims to evaluate the ability to utilize MRD detection to enable real-time treatment optimization for patients with #DLBCL. hubs.li/Q02-y31N0
Register for SOHO State of the Art Updates and Next Questions DON'T MISS this one-day event! Join us virtually on November 22, 2024, to hear @DrHKantarjian, @garciamanero, @bpromd, @calliecoombsmd, @SagarLonialMD as they tackle the most pressing questions!
Dr R Reshef @columbiacancer @ColumbiaMed presenting the potential of CAR T cell therapy in CTCL
At the NY cutaneous lymphoma consortium grand rounds chaired by Dr L Geskin 🎃 version! Looking forward to a great program @columbiacancer @ColumbiaMed
NEXT WEEK: Join us for ‘Recent Advances in the Diagnosis & Treatment of AL #Amyloidosis’ - a virtual conference on November 1, 2024 hosted by Columbia University, Department of Medicine. Info & registration: eventleaf.com/e/Amyloidosis2… #NephTwitter #NephX #nephrology #cardiology…
🙏 great meeting you!
I would like to share my key takeaway from the recent #LeukemiaLymphoma congress 🌟 Inspiring to witness the remarkable contributions of role models such as Dr. Joanna Rhodes @drjoannarhodes1, Dr. @JohnPLeonardMD, Dr. @drsarahruth, and Dr. Barbara Pro I was particularly…
New SOC in Adv stage HL
In patients with advanced-stage Hodgkin’s lymphoma, nivolumab added to chemotherapy resulted in greater 2-year progression-free survival than the addition of brentuximab vedotin to chemotherapy. Full trial results: nej.md/3A00MYS
Super proud of our super⭐️ Dr Yiran Emily Peng for receiving the Physician Partner of the Year award ! 👏👏👏@nyphospital @columbiacancer
We are thrilled to welcome Michel Sadelain, MD, PhD, a global pioneer in CAR-T therapies, to Columbia and the HICCC.
Columbia welcomes CAR-T pioneer Michel Sadelain, MD, PhD, as the inaugural director of the new Columbia Initiative for Cell Engineering and Therapy and director of the Cancer Cell Therapy Initiative at the Herbert Irving Comprehensive Cancer Center. ➡️columbiamed.link/3zCR9iI
👏Dr G Manero @garciamanero for an incredible meeting !#SOHO2024 #soho24
